xenograft model was used to assess the effects of miR-144-3p overexpression on tumorigenesis. Bioinformatics analysis and dualluciferase reporter assay were used to indentify AT-rich interactive domain 1A (ARID1A) as a direct target gene of miR-144-3p. Quantitative RT-PCR, Western blotting, and immunohistochemical (IHC) staining were used to explore ARID1A expression level of the mRNA and protein RESULTS: We found that miR-144-3p was the only upregulated miRNA both in clear cell renal cell carcinoma (ccRCC) tissue samples matched with normal kidney tissues and in paired preoperative matched with postoperative plasmas and miR-144-3p overexpression enhanced cell proliferation, clonogenicity, migration, invasion, and chemoresistance in ccRCC cells. Notably, the oncotumor activities of miR-144-3p were mediated by repressing the expression of ARID1A. The downregulation of ARIDIA could promote the function of miR-144-3p in cell proliferation, metastasis and chemoresistance. Consistently, ARID1A mRNA and protein levels were decreased in ccRCC and in nude mice, and they negatively correlated with miR-144-3p CONCLUSIONS: Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.
INTRODUCTION AND OBJECTIVES:
The estrogen receptor beta (ERb), first discovered in 1996, has been recognized as a protective nuclear receptor in many hormone-sensitive tumors, including breast and prostate cancers. Yet in contrast, ERb can also promote progression of bladder cancer. The roles of ERb in RCC, however, remain to be further elucidated. Here we found ERb could promote the RCC progression, and clinical sample investigation revealed that a higher ERb expression is correlated with a worse overall survival rate/a shorter disease-free survival in RCC patients. The identification of the ERb-HOTAIR-ceRNA axis may provide us new biomarkers and/or therapeutic targets to better suppress RCC progression in the future.
METHODS: RNAseq Data (TCGA, provisional of 537 RCC patients) were retrieved from the TCGA database. The role of ERb, and the relationship between ERb and HOTAIR were investigated thoroughly through in vitro and in vivo experiments. We established the orthotopic RCC model by implanting luciferase-labeled 786-O/Scr or 786-O/shERb cells, also transduced into 6-week-old female nude mice (n ¼ 8 mice per group). The non-invasive in vivo imaging system (IVIS) was used every 2 weeks to monitor tumor progression.
RESULTS: Here, we provide clinical evidence that ERb expression is correlated in a negative manner with the overall survival/ disease-free survival in RCC patients. Mechanism dissection revealed that targeting ERb with ERb-shRNA and stimulating the transactivation of ERb with 17b-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression. The ERb-modulated HOTAIR is able to function via antagonizing several microRNAs, including miR-138, -200c, -204, or -217 to impact various oncogenes, including ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1, and ZEB2, to promote RCC proliferation and invasion.
CONCLUSIONS: Our new finding from multiple RCC cell lines and the preclinical mouse RCC model as well as TCGA database analysis all conclude that ERb could play a key role to promote ccRCC progression. This study focused on mechanisms how ERb could promote RCC progression though transcriptionally up-regulating lncRNA HOTAIR and shifting the entire associated ceRNA and oncogene network. If supporting evidence continues to emerge, ERb may become a feasible therapy target for metastatic RCC treatment and emerge as one important biomarker for the prediction of overall survival and progression-free survival. METHODS: We detected miR-124 and MEG3 expression by quantitative real-time polymerase chain reaction. Oligonucleotides were used to over express miR-124. Cell proliferation, invasion and migration were done to examine effects on cancer cell proliferation. Luciferase assay was performed to verify the precise target of miR-124.
RESULTS: Here we found that miR-124 and MEG3 were both strongly reduced in RCC, and combined expression of miR-124 and MEG3 emerged as an independent prognostic factor in RCC patients. Overexpression of miR-124 or MEG3 in ACHN and 786-O cells inhibited cell proliferation, suppressed cell invasion and metastasis. Using DZNep and siRNA to knockdown EZH2, we found EZH2 induced the epigenetic silencing of miR-124 and MEG3 expression by H3K27me3. Assays in RCC ACHN and 786-O cells showed that miR-124 directly targeted the TET1 transcript and that its inhibition could result in the upregulation of MEG3. RIP assay indicated that MEG3 induced p53 protein accumulation, while ChIP assay demonstrated p53 was a positive transcriptional regulator of the miR-124 by promoter activation. These three crosstalks of interaction between miR-124 and MEG3 providing a plausible link for the two most downregulated and positive correlated non-coding RNAs. Finally, we proved that PTPN11 were the direct targets of miR-124 as well as the MEG3 and p53 regulated genes, through which mediating the tumor Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1201
suppressing function in inhibiting cell proliferation, invasion and migration. CONCLUSIONS: Considering the poor prognostic outcomes associated with reduced miR-124 and MEG3, our findings imply that these factors play important antitumor effects in RCC pathogenesis, and might serve as two prognostic biomarkers and molecular therapeutic targets.
Source of Funding: This project was supported by the National Natural Science Foundation of China (31372562, 81270788, 81470935, 81370805, 81402098, 81402087) METHODS: We investigated the expression profile of circRNAs in five primary metastatic and five non-metastatic ccRCC tumor samples using a high-throughput circRNA microarray. Bioinformatic analyses were applied to study these differentially expressed circRNAs. Furthermore, qRT-PCR was performed to confirm these results. The circ-FOXM1 expression levels as well as clinicopathological significance were evaluated in primary RCC clinical specimens and RCC cell lines. In vitro knockdown of circ-FOXM1 in RCC cell lines was used to determine its effect on cellular proliferation, migration, and invasion.
RESULTS: Here we identified 528 differentially expressed circRNAs in primary metastatic ccRCC as compared with primary nonmetastatic ccRCC, of which 282 were significantly upregulated and 246 were downregulated. Differential circRNAs expression between the two groups were validated by qRT-PCR assay. Bioinformatics was employed to predict the interaction of circRNAs and mRNAs in metastatic ccRCC. We further characterized one circRNA hsa_circ_0025036 derived from the FOXM1 gene and termed it as circ-FOXM1. The expression of circ-FOXM1 is often upregulated in primary metastatic ccRCC as compared with primary non-metastatic ccRCC. The level of circ-FOXM1 was observed as an independent prognostic marker for overall survival of patients with ccRCC. Moreover, circ-FOXM1 promotes migratory, invasive, and metastasis capacities of ccRCC cells.
CONCLUSIONS: Overall, the differential expression of multiple circRNAs and their clinical significance in metastatic ccRCC tissues as revealed by our study suggests that circ-FOXM1 is a novel metastatic factor and prognostic marker in ccRCC, we propose that circRNA-FOXM1 could be used as a potential target in metastatic ccRCC therapy.
Source of Funding: NONE

MP88-13 TUMOR SUPPRESSOR TSC1 IS A NEW HSP90 COCHAPERONE THAT FACILITATES FOLDING OF KINASE AND NON-KINASE CLIENTS
Mark Woodford, Rebecca Sager, Adam Blanden, Stewart Loh, Syracuse, NY; David Gutmann, St. Louis, MO; Oleg Shapiro, Dimitra Bourboulia, Syracuse, NY; Michael Wong, St. Louis, MO; Gennady Bratslavsky, Mehdi Mollapour*, Syracuse, NY INTRODUCTION AND OBJECTIVES: Mutation of either TSC1 or TSC2 causes tuberous sclerosis, a multisystem genetic syndrome that can lead to formation of benign tumors in the kidneys, lungs, and other organs and has also been linked to epilepsy and autism. The tumor suppressors Tsc1 and Tsc2 form the tuberous sclerosis complex (TSC), a regulator of mTOR activity. Tsc1 stabilizes Tsc2; however the precise mechanism remains elusive. Molecular chaperones such as heat shock protein-90 (Hsp90) are essential for the stability and activation of numerous signaling proteins, including tumor suppressors. The objective of this work was to determine the role of Hsp90 in the stability and activity of TSC. We hypothesize that Hsp90 mediates TSC formation and thus is essential for the stability of Tsc2.
METHODS: Tsc1-FLAG and Tsc2-FLAG were transiently expressed and isolated from HEK293 cells. Interacting proteins were identified by co-immunoprecipitation. Hsp90 chaperone function is coupled to its ATPase activity. We have developed an assay to measure this activity by determining the rate of ATP breakdown and inorganic phosphate production. Hsp90 was isolated from WT and TSC1-/-mice and assayed for ATPase activity in vitro.
RESULTS: Tsc2 interacts with the molecular chaperone Hsp90 both in vitro and in vivo. Treatment of HEK293 cells with Hsp90 inhibitors such as ganetespib or SNX2112 caused ubiquitination and proteasomal degradation of Tsc2; therefore Tsc2 is a new client of Hsp90. However, Tsc1 stability does not depend on Hsp90. Tsc1 potently decelerates Hsp90 ATPase activity and facilitates the interaction of Tsc2 and other clients with Hsp90. We also showed that Tsc1 competes with the activating co-chaperone Aha1 for binding to Hsp90, providing a reciprocal regulatory mechanism for chaperoning of kinase and non-kinase clients.
CONCLUSIONS: Tsc1 interacts with Tsc2 and protects Tsc2 from degradation. Many pathogenic mutations of Tsc2 destabilize the protein. Our data suggest that lack of interaction of pathogenic Tsc2 mutants with Tsc1 and consequently Hsp90 lead to their degradation. Further, these newly elucidated roles of Tsc1 and Tsc2 suggest a potential mechanism for the observed differences between TSC1 and TSC2 mutant disease. In the absence of Tsc2, Tsc1 will still perform its critical role as a co-chaperone of Hsp90. However when Tsc1 is lost, the stability of both Tsc2 and many other Hsp90 clients is dramatically reduced, leading to a different phenotypic manifestation. 
MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
Kazuyuki Numakura*, Akita, Japan; Jesse Novac, Jean-Christophe Pignon, Toni Choueiri, Sabina Signoretti, Boston, MA INTRODUCTION AND OBJECTIVES: Previous studies have shown that treatment with an mTOR inhibitor (mTORi) is effective against renal cell carcinomas (RCCs), but with limited efficacy and durability. The concept of a cancer stem cell may explain treatment failures in advanced RCCs, but there is no evidence to support this, especially regarding mTORi resistance. Notch, which converts aldehydes to carboxylic acids in the cell membrane, may contribute to the generation of a drug-tolerant tumor cell population. In this study, the relationship between cancer stem cell characteristics and Notch activity was assessed in RCC cells with acquired resistance to mTORi.
METHODS: Four RCC cell lines (786-O, A-498, 769-P, and UMRC-3) with the VHL gene anomaly were analyzed for IC50 values of e1202 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
